Home/Pipeline/CYC-126

CYC-126

Treatment-Resistant Depression (TRD)

Phase 2Lead program; foundational product candidate

Key Facts

Indication

Treatment-Resistant Depression (TRD)

Phase

Phase 2

Status

Lead program; foundational product candidate

Company

Cyclerion Therapeutics

About Cyclerion Therapeutics

Cyclerion Therapeutics is dedicated to advancing a new pipeline of therapeutics for neuropsychiatric diseases, with a primary focus on treatment-resistant depression (TRD). The company's strategy integrates therapies with validated mechanisms of action with a tech-enabled, personalized delivery system, aiming to create the first individualized treatment for TRD. Led by a team with deep experience in CNS drug development and commercialization, Cyclerion is positioned to address a significant market opportunity by targeting patients who have not responded to traditional antidepressant therapies. Their approach is grounded in clinical evidence and designed to maximize both safety and efficacy for this challenging patient population.

View full company profile

Therapeutic Areas

Neuropsychiatry Mental Health

Other Treatment-Resistant Depression (TRD) Drugs

Drug	Company	Phase	Status
SPN-820/821	Supernus Pharmaceuticals	Phase 2	Active
BHV-2100 (mGluR2/3 NAM)	Biohaven	Phase 1	Completed
PCN-101 (R-ketamine)	atai Life Sciences	Phase 2	Active
VLS-01 (DMT)	atai Life Sciences	Phase 1	Active
Salvianolic Acid B	atai Life Sciences	Preclinical	Active
GH001	GH Research	Phase 2b	Active
BMB-101	Bright Minds Biosciences	Phase 2	Active
MW-101	MindWalk Holdings	Phase 2	Active, not yet recruiting
NPH-101	Neuphoria Therapeutics	Phase 1/2	Active